Psychotic experiences (PEs) are associated with a range of mental and physical disorders, and disability, but little is known about the association between PEs and aspects of health-related quality of life (HRQoL). We aimed to investigate the association between PEs and five HRQoL indicators with various adjustments. Using data from the WHO World Mental Health surveys (n = 33,370 adult respondents from 19 countries), we assessed for PEs and five HRQoL indicators (self-rated physical or mental health, perceived level of stigma (embarrassment and discrimination), and social network burden). Logistic regression models that adjusted for socio-demographic characteristics, 21 DSM-IV mental disorders, and 14 general medical conditions were used to investigate the associations between the variables of interest. We also investigated dose-response relationships between PE-related metrics (number of types and frequency of episodes) and the HRQoL indicators. Those with a history of PEs had increased odds of poor perceived mental (OR = 1.5, 95% CI = 1.2-1.9) and physical health (OR = 1.3, 95% CI = 1.0-1.7) after adjustment for the presence of any mental or general medical conditions. Higher levels of perceived stigma and social network burden were also associated with PEs in the adjusted models. Dose-response associations between PE type and frequency metrics and subjective physical and mental health were non-significant, except those with more PE types had increased odds of reporting higher discrimination (OR = 2.2, 95% CI = 1.3-3.5). Our findings provide novel insights into how those with PEs perceive their health status.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371397 | PMC |
http://dx.doi.org/10.1016/j.schres.2018.04.044 | DOI Listing |
Neurology
January 2025
Department of Neurology, National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, India; and.
A 16-year-old adolescent girl presented with progressive walking imbalance, uncoordination of her limbs, impaired proprioceptive sensation distal to her wrists and ankles, and sensorineural hearing loss. Her evaluation revealed diffuse cerebellar atrophy, a demyelinating neuropathy, and hypergonadotropic hypogonadism. In this article, we present a systematic approach to a patient with early-onset ataxia, cerebellar atrophy, and demyelinating neuropathy.
View Article and Find Full Text PDFInt J Methods Psychiatr Res
March 2025
Mental Health, Health Care and Social Welfare, Finnish Institute for Health and Welfare (THL), Helsinki, Finland.
Objectives: We implemented the first national patient experience survey, with novel patient-reported experience measures (PREMs), in out- and inpatient mental health and substance use services in Finland.
Methods: The Outpatient Experience Scale (OPES) and the Inpatient Experience Scale (IPES) were co-designed with experts by experience and professionals. The survey was carried out in 2021 in 435 treatment facilities.
ACS Sens
December 2024
College of Integrated Circuits, Taiyuan University of Technology, Taiyuan 030024, China.
By analyzing facial features to perform expression recognition and health monitoring, facial perception plays a pivotal role in noninvasive, real-time disease diagnosis and prevention. Current perception routes are limited by structural complexity and the necessity of a power supply, making timely and accurate monitoring difficult. Herein, a self-powered poly(vinyl alcohol)-gellan gum-glycerol thermogalvanic gel patch enabling facial perception is developed for monitoring emotions and atypical pathological states.
View Article and Find Full Text PDFSchizophr Bull
December 2024
Clinical and Translational Sciences Lab, Douglas Research Centre, Montreal, Quebec H4H 1R3, Canada.
Background And Hypothesis: Cognitive impairments are particularly disabling for patients with a psychotic disorder and often persist despite optimization of antipsychotic treatment. Thus, motivating an extension of the research focus on the endocannabinoid system. The aim of this study was to evaluate group differences in brain fatty acid amid hydrolase (FAAH), an endocannabinoid enzyme between first-episode psychosis (FEP), individuals with clinical high risk (CHR) for psychosis and healthy controls (HCs).
View Article and Find Full Text PDFFam Pract
December 2024
Department of Medicine, Larner College of Medicine, University of Vermont, 89 Beaumont Ave, Burlington, VT 05405, United States.
Background: During coronavirus disease 2019 (COVID-19), people managing multiple chronic conditions (MCCs) experienced barriers to obtaining needed medications. The purposes of this paper are to (i) determine risk factors for difficulty obtaining medications during COVID-19, (ii) document reasons for the difficulty, and (iii) evaluate the impact on later physical and mental health outcomes.
Method: In a randomized controlled trial conducted in 2016-2021, 1969 adult primary care patients were surveyed about physical and mental health both before and during COVID-19.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!